Is sequential low-dose immunotherapy the preferred treatment in cadaveric renal transplantation?
Posner
M P
MP
Department of Surgery, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298.
Mendez-Picon
G
G
King
A
A
Nelson
K P
KP
Spicer
H G
HG
Lee
H M
HM
D000961:Antilymphocyte Serum / Q000008:administration & dosage* / Q000627:therapeutic use; D001379:Azathioprine / Q000008:administration & dosage* / Q000627:therapeutic use; D002102:Cadaver; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D003524:Cyclosporins / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000187:drug effects; D006085:Graft Survival / Q000187:drug effects; D006801:Humans; D016030:Kidney Transplantation; D011241:Prednisone / Q000008:administration & dosage* / Q000627:therapeutic use
D000961:Antilymphocyte Serum; D003524:Cyclosporins; D003404:Creatinine; D001379:Azathioprine; D011241:Prednisone